• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatable traits in interstitial lung diseases: a call to action.

作者信息

Amati Francesco, Spagnolo Paolo, Oldham Justin M, Ryerson Christopher J, Stainer Anna, Gramegna Andrea, Mantero Marco, Lacedonia Donato, Sverzellati Nicola, Richeldi Luca, Blasi Francesco, Aliberti Stefano

机构信息

Department of Biomedical Sciences, Humanitas University, Milan 20072, Italy; IRCCS Humanitas Research Hospital, Respiratory Unit, Milan, Italy.

Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health; University of Padua, Padua, Italy.

出版信息

Lancet Respir Med. 2023 Feb;11(2):125-128. doi: 10.1016/S2213-2600(23)00002-4. Epub 2023 Jan 13.

DOI:10.1016/S2213-2600(23)00002-4
PMID:36646100
Abstract
摘要

相似文献

1
Treatable traits in interstitial lung diseases: a call to action.间质性肺疾病的可治疗特征：行动呼吁。
Lancet Respir Med. 2023 Feb;11(2):125-128. doi: 10.1016/S2213-2600(23)00002-4. Epub 2023 Jan 13.
2
Reply: The concept and application of the treatable traits approach in interstitial lung disease and other chronic respiratory diseases.回复：可治疗特征方法在间质性肺疾病和其他慢性呼吸道疾病中的概念与应用。
Eur Respir J. 2023 Nov 9;62(5). doi: 10.1183/13993003.01744-2023. Print 2023 Nov.
3
Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases.特发性肺纤维化和其他间质性肺疾病中的肺微生物组。
Int J Mol Sci. 2022 Jan 17;23(2):977. doi: 10.3390/ijms23020977.
4
Treatable traits: a comprehensive precision medicine approach in interstitial lung disease, but why were acute exacerbations not considered?可治疗特征：间质性肺疾病的综合精准医学方法，但为何未考虑急性加重情况？
Eur Respir J. 2023 Sep 21;62(3). doi: 10.1183/13993003.01449-2023. Print 2023 Sep.
5
Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases.进行性纤维性间质性肺疾病的诊断和治疗中的医疗保健利用和费用。
Eur Respir Rev. 2018 Dec 21;27(150). doi: 10.1183/16000617.0078-2018. Print 2018 Dec 31.
6
Progressive fibrosis in interstitial lung diseases - proposed definition and management.间质性肺疾病的进行性纤维化 - 建议的定义和管理。
Adv Respir Med. 2021;89(5):505-510. doi: 10.5603/ARM.a2021.0103.
7
Clinical approach to interstitial lung disease.间质性肺疾病的临床处理方法
Semin Ultrasound CT MR. 2002 Aug;23(4):269-74. doi: 10.1016/s0887-2171(02)90016-8.
8
[Interstitial lung diseases. A turning point in diagnosis and treatment].[间质性肺疾病。诊断与治疗的转折点]
Rev Prat. 2014 Sep;64(7):915-6.
9
[Acute on chronic respiratory failure in interstitial pneumonias].[间质性肺炎中的急性慢性呼吸衰竭]
Med Klin Intensivmed Notfmed. 2015 Apr;110(3):188-96. doi: 10.1007/s00063-014-0388-6. Epub 2014 Aug 16.
10
Task force on chronic interstitial lung disease in immunocompetent children.免疫功能正常儿童慢性间质性肺疾病特别工作组
Eur Respir J. 2004 Oct;24(4):686-97. doi: 10.1183/09031936.04.00089803.

引用本文的文献

1
Diagnostic and prognostic trajectories of interstitial lung diseases after the multidisciplinary discussion.多学科讨论后间质性肺疾病的诊断和预后轨迹
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251323487. doi: 10.1177/17534666251323487. Epub 2025 Mar 13.
2
Monthly pulse methylprednisolone infusions in patients with non-idiopathic pulmonary fibrosis interstitial lung diseases: a single-center retrospective analyses.非特发性肺纤维化间质性肺疾病患者每月静脉输注甲泼尼龙：一项单中心回顾性分析
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251342661. doi: 10.1177/17534666251342661. Epub 2025 May 30.
3
Treatable traits in interstitial lung disease: a narrative review.
间质性肺疾病的可治疗特征：一篇叙述性综述
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251335774. doi: 10.1177/17534666251335774. Epub 2025 May 3.
4
The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis.合并症对特发性肺纤维化患者抗纤维化治疗中断的影响。
Pharmaceuticals (Basel). 2025 Mar 14;18(3):411. doi: 10.3390/ph18030411.
5
Patient-centered care in pulmonary fibrosis: access, anticipate, and act.肺纤维化中的以患者为中心的护理：获得、预见和行动。
Respir Res. 2024 Nov 1;25(1):395. doi: 10.1186/s12931-024-02997-7.
6
First Report of the Prevalence at Baseline and after 1-Year Follow-Up of Treatable Traits in Interstitial Lung Diseases.间质性肺疾病中可治疗特征的基线患病率及1年随访后的首次报告。
Biomedicines. 2024 May 9;12(5):1047. doi: 10.3390/biomedicines12051047.
7
Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review.血管活性药物治疗与间质性肺疾病相关的肺动脉高压：系统评价。
BMJ Open Respir Res. 2024 Mar 13;11(1):e002161. doi: 10.1136/bmjresp-2023-002161.
8
Response to: are there over 200 distinct types of interstitial lung diseases?回应：间质性肺疾病是否有超过200种不同类型？
Respir Res. 2024 Mar 6;25(1):114. doi: 10.1186/s12931-024-02751-z.
9
Treatable traits and challenges in the clinical management of non-tuberculous mycobacteria lung disease in people with cystic fibrosis.囊性纤维化患者中非结核分枝杆菌肺病的临床管理中可治疗的特征和挑战。
Respir Res. 2023 Dec 16;24(1):316. doi: 10.1186/s12931-023-02612-1.
10
Walking the path of treatable traits in interstitial lung diseases.在间质性肺疾病中探寻可治疗的特征。
Respir Res. 2023 Oct 24;24(1):251. doi: 10.1186/s12931-023-02554-8.